These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19364646)

  • 1. Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.
    Ekblad T; Orlova A; Feldwisch J; Wennborg A; Karlström AE; Tolmachev V
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3912-4. PubMed ID: 19364646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
    Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A
    Bioconjug Chem; 2008 Dec; 19(12):2568-76. PubMed ID: 19035668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
    Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
    Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine.
    Ahlgren S; Andersson K; Tolmachev V
    Nucl Med Biol; 2010 Jul; 37(5):539-46. PubMed ID: 20610158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules.
    Hofström C; Altai M; Honarvar H; Strand J; Malmberg J; Hosseinimehr SJ; Orlova A; Gräslund T; Tolmachev V
    J Med Chem; 2013 Jun; 56(12):4966-74. PubMed ID: 23692562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
    Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
    Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.
    Tolmachev V; Hofström C; Malmberg J; Ahlgren S; Hosseinimehr SJ; Sandström M; Abrahmsén L; Orlova A; Gräslund T
    Bioconjug Chem; 2010 Nov; 21(11):2013-22. PubMed ID: 20964447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.
    Ekblad T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsén L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2245-55. PubMed ID: 18594815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl.
    D'Andrea LD; Testa I; Panico M; Di Stasi R; Caracò C; Tarallo L; Arra C; Barbieri A; Romanelli A; Aloj L
    Biopolymers; 2008; 90(5):707-12. PubMed ID: 18615495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I.
    Hofstrom C; Orlova A; Altai M; Wangsell F; Graslund T; Tolmachev V
    J Med Chem; 2011 Jun; 54(11):3817-26. PubMed ID: 21524142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
    Mume E; Orlova A; Larsson B; Nilsson AS; Nilsson FY; Sjöberg S; Tolmachev V
    Bioconjug Chem; 2005; 16(6):1547-55. PubMed ID: 16287254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
    Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
    Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
    Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
    J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
    Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.
    Steffen AC; Almqvist Y; Chyan MK; Lundqvist H; Tolmachev V; Wilbur DS; Carlsson J
    Oncol Rep; 2007 May; 17(5):1141-7. PubMed ID: 17390057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
    Wållberg H; Löfdahl PK; Tschapalda K; Uhlén M; Tolmachev V; Nygren PK; Ståhl S
    Protein Expr Purif; 2011 Mar; 76(1):127-35. PubMed ID: 21029777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.
    Altai M; Honarvar H; Wållberg H; Strand J; Varasteh Z; Rosestedt M; Orlova A; Dunås F; Sandström M; Löfblom J; Tolmachev V; Ståhl S
    Eur J Med Chem; 2014 Nov; 87():519-28. PubMed ID: 25282673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.